Axios Vitals: Patents = profits (Article 3)
AbbVie faces hepatitis C patent challenge in India
Brief: AbbVie Hepatitis C Treatment Patents Challenged In India For Evergreening
Conceptualizing Minimum Core Beyond Affordable Goods And Services – Trade For Human Rights As A Minimum Core Obligation
I-MAK & Patients for Affordable Drugs File Amicus Brief with the US Supreme Court in support of RPX Corp in RPX Corp. v. Chanbond LLC
I-MAK & Delhi Network of Positive People File Opposition to Prevent AbbVie Patent Grant on Hepatitis C Treatment
The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
FDA publishes shame list of firms fighting generic competitors
FDA shames companies accused of blocking generic drug development